SBA PreQual Medical Device Company | Proprietary

Broker presents an SBA pre-qualified Medical Technology Business operating at the intersection of robotics, AI-enabled precision, and procedural efficiency within the rapidly expanding hair restoration market. This company has developed proprietary, FDA-compliant systems that materially improve surgical consistency, speed, and outcomes for physicians while lowering procedural fatigue and reducing patient recovery time. Since launching in 2018, the business has established itself as a trusted solution provider to clinics across the United States by delivering enterprise-grade technology at a fraction of the cost of legacy systems, removing a key financial barrier to adoption and accelerating market penetration.

This business is SBA pre-qualified, allowing qualified buyers to acquire the company with as little as 10% equity injection and the balance financed through an SBA-backed loan amortized over up to 10 years. This structure significantly enhances cash-on-cash returns while preserving liquidity for growth initiatives such as international expansion, additional system development, and sales team scaling. SBA eligibility also reflects the company’s strong operating history, defensible revenue model, and lender-friendly financial profile, making this an attractive opportunity for buyers seeking leveraged acquisition financing on favorable terms.

Key Valuation Points
• SBA Pre-Qualified
• Founded in 2018 with a mission to revolutionize hair restoration.
• Projected $3.0M revenue by 2026 with aggressive expansion plans.
• Holds over 22 patents protecting cutting-edge technologies.
• Production capacity of 2-3 units per day, scalable to meet demand.
• Complies with US FDA Class 1, 510K exempt regulations.
• Overseas expansion requires $0.5M capital investment.

The company generates revenue through the direct sale of high-ticket robotic systems supported by training, certification, and ongoing customer support, creating a sticky ecosystem that extends well beyond the initial equipment purchase. Clinics adopting the platform benefit from predictable workflows, improved aesthetic results, and scalable procedure capacity, which has driven strong conversion rates and repeat system adoption. Demand is supported by a growing population seeking restorative procedures, combined with physicians’ increasing willingness to invest in technology that improves throughput and clinical outcomes without expanding staff.

Operations are streamlined and production-ready, with the ability to manufacture multiple units daily from a centralized facility. The business holds a defensible intellectual property position supported by issued patents that protect its robotics, software, and procedural innovations. Sales are driven through a direct outreach model with substantial deal sizes, allowing the company to scale revenue efficiently without reliance on mass marketing or broad advertising spend.

WC 3905